Wegovy Maker Novo Nordisk Lifts Guidance After Second-Quarter Boost
By Mauro Orru
Novo Nordisk said annual sales and operating profit should fall less than it previously expected following a boost in the second quarter.
The Danish drugmaker said it expected sales and operating profit on an adjusted basis to decline up to 6% at constant exchange rates this year, better than prior guidance of a 4% to 12% decline for both metrics.
The company said adjusted sales in the second quarter grew 7% on year to 78.49 billion Danish kroner, equivalent to $12.08 billion. Meanwhile, adjusted operating profit grew 11% to 33.39 billion kroner.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
August 04, 2026 13:06 ET (17:06 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
This Once-Hot AI Stock Now Looks Deeply Undervalued
3 Stocks to Sell and 3 Stocks to Buy for November
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
5 Stocks to Buy Trading at Big Discounts
